Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
12 hedge funds and large institutions have $556K invested in Statera Biopharma, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
24% less capital invested
Capital invested by funds: $727K → $556K (-$171K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$15.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.41K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$620 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$116 |
| 5 |
RIA
Realta Investment Advisors
Wilmington,
Delaware
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$83.3K |
| 2 |
BlackRock
New York
|
-$14.3K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$6 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $440K | +$15.3K | +9,900 | +3% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $77K | -$83.3K | -53,800 | -50% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $25K | +$1.41K | +910 | +5% |
|
|
4
BlackRock
New York
| $6K | -$14.3K | -9,234 | -68% |
|
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | -$6 | -4 | -0.1% |
|
6
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $2K | – | – | – |
|
|
7
Bank of America
Charlotte,
North Carolina
| $1K | +$620 | +400 | +267% |
|
|
RIA
8
Realta Investment Advisors
Wilmington,
Delaware
| – | +$8 | +5 | New |
|
|
9
Wells Fargo
San Francisco,
California
| – | +$116 | +75 | +163% |
|
STAB Hedge Fund Activity: Q2 2019 in Review
12 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2019, worth a combined $556K — down 24% from $727K a quarter earlier.
Fund positioning in STAB was balanced in Q2 2019: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $15.3K. The largest seller was Vanguard Group, cutting an estimated $83.3K.
- 12 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $556K of Statera Biopharma, Inc. Common Stock stock for Q2 2019, down 24% quarter-over-quarter.
- 1 fund opened new Statera Biopharma, Inc. Common Stock positions in Q2 2019 and 1 closed out, a net change of 0 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q2 2019 was Renaissance Technologies, an estimated $15.3K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q2 2019 was Vanguard Group, an estimated $83.3K sold.
Based on aggregated 13F filings for Q2 2019.